Background: Cheyne-Stokes respiration frequently occurs in patients with congestive heart failure (CHF). Adaptive servoventilation (ASV) is a novel therapy with potential benefits. This prospective randomized trial investigated the effects of ASV on myocardial function and physical capacity. Methods: Patients with severe CHF, despite optimal cardiac medication and/or left ventricular ejection fraction (LVEF) ≤40% and Cheyne-Stokes breathing for >25% of sleeping time were included. Fifty-one patients, age 57-81 years (4 were women), were randomized to either an ASV or a control group; 30 patients completed the study (15 from each group). The primary end point was any change in LVEF. The secondary end points were alterations in physical capacity according to the 6-min walk test or the New York Heart Association (NYHA) class. Results: In the ASV-treatment group, LVEF improved from baseline (32 ± 11%) to study end (36 ± 13%), p = 0.013. The 6-min walk test improved from 377 ± 115 to 430 ± 123 m (p = 0.014) and the NYHA class from 3.2 (3.0-3.0) to 2.0 (2.0-3.0) (p < 0.001). No changes occurred in the control group. Conclusion: Three months of ASV treatment improved LVEF and physical capacity in CHF patients with Cheyne-Stokes respiration. These results suggest that ASV may be a beneficial supplement to standard medication in these patients.

1.
Naughton MT: Sleep disorders in patients with congestive heart failure. Curr Opin Pulm Med 2003;9:453-458.
2.
Naughton MT: Pathophysiology and treatment of Cheyne-Stokes respiration. Thorax 1998;53:514-518.
3.
Hanly PJ, Zuberi-Khokhar NS: Increased mortality associated with Cheyne-Stokes respiration in patients with congestive heart failure. Am J Respir Crit Care Med 1996;153:272-276.
4.
Javaheri S, Parker TJ, Wexler L, Michaels SE, Stanberry E, et al: Occult sleep-disordered breathing in stable congestive heart failure. Ann Intern Med 1995;122:487-492.
5.
Lorenzi-Filho G, Genta PR, Figueiredo AC, Inoue D: Cheyne-Stokes respiration in patients with congestive heart failure: causes and consequences. Clinics (Sao Paulo) 2005;60:333-344.
6.
Oldenburg O, Lamp B, Faber L, Teschler H, Horstkotte D, et al: Sleep-disordered breathing in patients with symptomatic heart failure: a contemporary study of prevalence in and characteristics of 700 patients. Eur J Heart Fail 2007;9:251-257.
7.
Sin DD, Logan AG, Fitzgerald FS, Liu PP, Bradley TD: Effects of continuous positive airway pressure on cardiovascular outcomes in heart failure patients with and without Cheyne-Stokes respiration. Circulation 2000;102:61-66.
8.
Traverse JH, Henry TD, Moye LA: Is the measurement of left ventricular ejection fraction the proper end point for cell therapy trials? An analysis of the effect of bone marrow mononuclear stem cell administration on left ventricular ejection fraction after ST-segment elevation myocardial infarction when evaluated by cardiac magnetic resonance imaging. Am Heart J 2011;162:671-677.
9.
Philippe C, Stoica-Herman M, Drouot X, Raffestin B, Escourrou P, et al: Compliance with and effectiveness of adaptive servoventilation versus continuous positive airway pressure in the treatment of Cheyne-Stokes respiration in heart failure over a six month period. Heart 2006;92:337-342.
10.
Teschler H, Dohring J, Wang YM, Berthon-Jones M: Adaptive pressure support servo-ventilation: a novel treatment for Cheyne-Stokes respiration in heart failure. Am J Respir Crit Care Med 2001;164:614-619.
11.
Javaheri S, Parker TJ, Liming JD, Corbett WS, Nishiyama H, et al: Sleep apnea in 81 ambulatory male patients with stable heart failure. Types and their prevalences, consequences, and presentations. Circulation 1998;97:2154-2159.
12.
Oldenburg O, Schmidt A, Lamp B, Bitter T, Muntean BG, et al: Adaptive servoventilation improves cardiac function in patients with chronic heart failure and Cheyne-Stokes respiration. Eur J Heart Fail 2008;10:581-586.
13.
Bitter T, Westerheide N, Prinz C, Hossain MS, Vogt J, et al: Cheyne-Stokes respiration and obstructive sleep apnoea are independent risk factors for malignant ventricular arrhythmias requiring appropriate cardioverter-defibrillator therapies in patients with congestive heart failure. Eur Heart J 2011;32:61-74.
14.
Fanfulla F, Mortara A, Maestri R, Pinna GD, Bruschi C, et al: The development of hyperventilation in patients with chronic heart failure and Cheyne-Strokes respiration: a possible role of chronic hypoxia. Chest 1998;114:1083-1090.
15.
Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, et al: Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989;2:358-367.
16.
Enright PL: The six-minute walk test. Respir Care 2003;48:783-785.
17.
Edvardsen T, Haugaa KH: Imaging assessment of ventricular mechanics. Heart 2011;97:1349-1356.
18.
Haugaa KH, Smedsrud MK, Steen T, Kongsgaard E, Loennechen JP, et al: Mechanical dispersion assessed by myocardial strain in patients after myocardial infarction for risk prediction of ventricular arrhythmia. JACC Cardiovasc Imaging 2010;3:247-256.
19.
Giannuzzi P, Temporelli PL, Corra U, Tavazzi L: Antiremodeling effect of long-term exercise training in patients with stable chronic heart failure: results of the Exercise in Left Ventricular Dysfunction and Chronic Heart Failure (ELVD-CHF) Trial. Circulation 2003;108:554-559.
20.
Piepoli MF, Davos C, Francis DP, Coats AJ: Exercise training meta-analysis of trials in patients with chronic heart failure (ExTraMATCH). BMJ 2004;328:189.
21.
Jilek C, Krenn M, Sebah D, Obermeier R, Braune A, et al: Prognostic impact of sleep disordered breathing and its treatment in heart failure: an observational study. Eur J Heart Fail 2011;13:68-75.
22.
Yumino D, Wang H, Floras JS, Newton GE, Mak S, et al: Relationship between sleep apnoea and mortality in patients with ischaemic heart failure. Heart 2009;95:819-824.
23.
Lanfranchi PA, Braghiroli A, Bosimini E, Mazzuero G, Colombo R, et al: Prognostic value of nocturnal Cheyne-Stokes respiration in chronic heart failure. Circulation 1999;99:1435-1440.
24.
Hastings PC, Vazir A, Meadows GE, Dayer M, Poole-Wilson PA, et al: Adaptive servo-ventilation in heart failure patients with sleep apnea: a real world study. Int J Cardiol 2010;139:17-24.
25.
Bradley TD: Continuous positive airway pressure for congestive heart failure. CMAJ 2000;162:535-536.
26.
Kasai T, Kasagi S, Maeno K-i, Dohi T, Kawana F, et al: Adaptive servo-ventilation in cardiac function and neurohormonal status in patients with heart failure and central sleep apnea nonresponsive to continuous positive airway pressure. JACC Heart Failure 2013;1:58-63.
27.
Zhang XL, Yin KS, Li XL, Jia EZ, Su M: Efficacy of adaptive servoventilation in patients with congestive heart failure and Cheyne-Stokes respiration. Chin Med J (Engl) 2006;119:622-627.
28.
Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA: Use of NT-proBNP in routine testing and comparison to BNP. Eur J Heart Fail 2004;6:289-293.
29.
Pepperell JC, Maskell NA, Jones DR, Langford-Wiley BA, Crosthwaite N, et al: A randomized controlled trial of adaptive ventilation for Cheyne-Stokes breathing in heart failure. Am J Respir Crit Care Med 2003;168:1109-1114.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.